Armata Pharmaceuticals, Inc.
ARMP
Rank in Stocks
#18144
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology... Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Share Price
$3.89
Last synced: 2026-11-11
Market Cap
$142.95M
Change (1 day)
3.73%
Change (1 year)
-41.85%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Armata Pharmaceuticals, Inc. (ARMP)
Category
Healthcare
Operating Margin for Armata Pharmaceuticals, Inc. (ARMP)
Operating Margin as of November 2026 TTM: -1,233.59%
According to Armata Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is -1,233.59%. At the end of 2025 the company had an operating margin of -636.66%.
Operating Margin history for Armata Pharmaceuticals, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,233.59% | 93.76% |
| 2025 | -636.66% | -22.38% |
| 2024 | -820.18% | -9.16% |
| 2023 | -902.85% | 34.60% |
| 2022 | -670.77% | 25.98% |
| 2021 | -532.45% | -79.70% |
| 2020 | -2,622.96% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2017 | -14,048.70% | 56.24% |
| 2016 | -8,991.54% | 317.62% |
| 2015 | -2,153.05% | -37.59% |
| 2014 | -3,449.88% | -25.18% |
| 2013 | -4,611.08% | 660.88% |
| 2012 | -606.02% | -4,462.99% |
| 2009 | 13.89% | -105.72% |
| 2008 | -242.80% | 51.54% |
| 2007 | -160.22% | -56.97% |
| 2006 | -372.35% | 32.30% |
| 2005 | -281.45% | 79.07% |
| 2004 | -157.17% | 60.23% |
| 2003 | -98.09% | 3.08% |
| 2002 | -95.16% | -37.19% |
| 2001 | -151.50% | -62.28% |
| 2000 | -401.69% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.03% |
US
|
|
| -149.01% | -99.88% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.03% |
BE
|
|
| 29.35% | -100.02% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Armata Pharmaceuticals, Inc.'s operating margin
What is Armata Pharmaceuticals, Inc.'s operating margin?
Armata Pharmaceuticals, Inc.'s operating margin is -1,233.59%, as of Nov 2026.
What was Armata Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, Armata Pharmaceuticals, Inc.'s operating margin was -636.66%, compared with -820.18% in 2024.
How has Armata Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Armata Pharmaceuticals, Inc.'s operating margin was highest in 2021 (-532.45%) and lowest in 2020 (-2,622.96%).
How does Armata Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Armata Pharmaceuticals, Inc.'s operating margin (-1,233.59%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.